Tuesday, 19 Nov 2019

You are here

Surgical Decompression Ineffective for Subacromial Shoulder Pain

Lancet reports that a common surgical intervention, arthroscopic sub-acromial decompression is ineffective compared to arthroscopy or no surgery at all.

A multicentre, randomised, placebo-controlled trial included surgically naive patients who had subacromial pain for > 3 months with intact rotator cuff tendons.  These patients were refractory despite prior exercise therapy and at least one steroid injection. Patients were randomized to receive either A) arthroscopic subacromial decompression, B) arthroscopy only (no removal of bone and soft tissue), or C) no treatment intervention.

The primary outcome was the Oxford Shoulder Score (0 [worst] to 48 [best]) at 6 months.

The study enrolled 313 patients (106 to decompression surgery, 103 to arthroscopy only, and 104 to no treatment).  At 6 months, there was data for 90 patients assigned to decompression, 94 to arthroscopy, and 90 to no treatment.

The Oxford Shoulder Scores did not differ between the two surgical groups at 6 months (decompression mean 32·7 points vs arthroscopy mean 34·2 points). There was little benefit over no treatment (mean 29·4 points). While this was statisticially significant (p=0·0014), such differences were not felt to be clinically meaningful.

There were six study-related frozen shoulders (in two patients in each group) and no other complications.

Surgical intervention for subacromial shoulder pain failed to yield clinically important results and surgical decompression appeared to offer no extra benefit over arthroscopy only. 

These data imply a greater role for conservative management measures when treating subacromial shoulder pain. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Mallinckrodt Receives SEC Subpoena

Reuters reports that Mallinckrodt Plc has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.